Public-registry site landscape for NCT07692165, “A Phase Ib/IIa Study of INT-210 Capsules in Participants With Active Ulcerative Colitis”, a Ulcerative Colitis (UC) study sponsored by Innatus Therapeutics (Shanghai) Co., Ltd.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07692165 (registry record) |
| Study title | A Phase Ib/IIa Study of INT-210 Capsules in Participants With Active Ulcerative Colitis |
| Official title | A Multicenter, Randomized, Open-label Clinical Study to Evaluate the Safety and Efficacy of INT-210 Capsules in Participants With Active Ulcerative Colitis |
| Sponsor | Innatus Therapeutics (Shanghai) Co., Ltd. |
| Condition(s) | Ulcerative Colitis (UC) |
| Phase | PHASE1 / PHASE2 |
| Listed sites | 15 |
| Intervention(s) | INT-210 Capsule |
| Site countries | China |
At The Sixth Affiliated Hospital, Sun Yat-sen University — one of the facilities listed on this trial — 7 other studies are actively recruiting Ulcerative Colitis (UC) patients at the same facility (public registry, as of July 2026). Facility-level recruiting density is one of the strongest public correlates of enrollment pace in an indication.
Patient-friendly overview of this study: eichor.com/study/NCT07692165.
Eichor generates a preliminary site-risk snapshot for NCT07692165 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
